ANTHOS THERAPEUTICS
Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases

John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics.

Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated (NYSE: BXLT), formerly Baxter BioScience (NYSE: BAX).

Prior to joining Baxter in August 2012, Mr. Glasspool was Head of Region Europe and Novartis Vaccines & Diagnostics (NYSE: NVS), a member of the V&D Executive Committee. Mr. Glasspool served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012.

Previously, Mr. Glasspool was Head of Global Pricing & Market Access and Head of Global Commercial Operations in Novartis Pharma, where he led the functions in embedding the needs of customers and consumers for brands at all stages of their lifecycle development, launch, and in market. Mr. Glasspool joined Novartis as Head of Marketing for Neuroscience. He was promoted to Global Head Cardiovascular & Metabolism Business Franchise in 2006, during which time he grew the franchise sales over a three-year period.

Nicholas Galakatos, Ph.D. is Chairman of the Board of Directors of Anthos Therapeutics.

Dr. Galakatos is the Head of Blackstone Life Sciences, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception in 2005. Dr. Galakatos has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships and diagnostics, from startups to commercial-stage companies. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm.

Paris Panayiotopoulos is a member of the Board of Directors of Anthos Therapeutics.

Mr. Panayiotopoulos is a Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Mr. Panayiotopoulos is focused on growth investments in the biopharmaceutical space.

In over twenty years in the biopharmaceutical industry, Mr. Panayiotopoulos has served on the Board of Directors of a number of start-up to commercialization stage companies, as CEO and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA, sold to Takeda Pharmaceuticals in 2017), and as President of the US, Japan and Serono R&D Institute biopharmaceutical businesses of Merck KgaA (FWB: MRK).

Scott Beardsley is a member of the Board of Directors of Anthos Therapeutics.

Mr. Beardsley joined Novo Ventures (US) Inc. in San Francisco, California in 2012. Previously, he was a board member of Aerocrine AB.

From 2009-2012, Mr. Beardsley was part of Novo A/S’ Growth Equity team. Prior to joining Novo A/S he was a Managing Director at JP Morgan in San Francisco, heading the firm's West Coast biopharmaceuticals effort. Prior to that, Mr. Beardsley led Piper Jaffray's US biopharmaceuticals investment banking practice and was a member of the Health Care Group at Montgomery Securities. During his tenure as an investment banker, Mr. Beardsley originated and executed numerous transactions.

Mr. Beardsley holds an MBA from UCLA's Anderson Graduate School of Management and a BS from Colorado State University.

Ari Brettman, M.D. is a member of the Board of Directors of Anthos Therapeutics.

Dr. Brettman is a Principal at Blackstone Life Sciences, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014.

Dr. Brettman is focused on investments across the firm's portfolio, including startups and partnerships with pharmaceutical companies. Prior to Clarus, Dr. Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital. Dr. Brettman was also an NIH-sponsored post-doctoral fellow at the MGH Center for Systems Biology, where he studied the autophagy of lipid droplets and used electronic medical record-based big data analytics at Partners Healthcare to conduct clinical research and improve disease management. Dr. Brettman is a member of the Board of Directors of Praxis Precision Medicines, a startup in genetically defined neuropsychiatric disorders.

Dr. Shaun R. Coughlin, M.D, Ph.D. is an Observer to the Board of Directors of Anthos Therapeutics.

Dr. Coughlin has been Global Head of Cardiovascular & Metabolism at Novartis AG (NYSE: NVS) since August 2017.

Dr. Coughlin was appointed Professor of Medicine in 1996 and Professor of Molecular and Cellular Pharmacology in 1997 at the University of California, San Francisco ('UCSF'), where he served until 2017.

During his time at UCSF, Dr. Coughlin also served as the Director of the Cardiovascular Research Institute and the Director of Daiichi Research Center. Dr. Coughlin is also a Member of the editorial boards of Trends in Cardiovascular Medicine, Molecular Medicine and Journal of Clinical Investigation.

Jonathan Freeman, Ph.D. is Chief Operating Officer at Anthos Therapeutics.

Dr. Freeman is a Blackstone Life Sciences Senior Advisor and has over 20 years of practical industry experience within the healthcare private equity, start-up, business development, corporate development, and M&A sectors. Dr. Freeman previously served as Senior Vice President of Strategy / Portfolio Management, and Head of Business Development and Licensing at Merck KgaA (FWB: MRK); CBO, Vedanta Biosciences (LSE: PRTC); Head of M&A and Licensing at Baxter International (NYSE: BAX); and Director of Corporate Development at Serono (NYSE: SRA).

Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the ICRF (now CRUK), an MBA jointly from the Universities of Versailles, Paris-Saclay, and Webster, St Louis, and both an MA and First-Class BA (Hons) from Cambridge University. Jonathan was previously Vice President of the Swiss PLG, an EMBO fellow at the Swiss Institute of Experimental Cancer Research (ISREC) and has authored several peer-reviewed scientific papers in the fields of oncology and drug metabolism.

Debra Freedholm is Head of Clinical Operations at Anthos Therapeutics.

Ms. Freedholm is a clinical and business operations executive with more than 25 years’ experience in the pharmaceutical industry in a variety of leadership roles across Clinical Research, Clinical Operations, Business Operations and Corporate Licensing at Bristol-Myers Squibb (NYSE: BMS) and Merck (NYSE: MRK).

Ms. Freedholm has extensive experience in building new organizations in diverse areas across pharma, academic institutions and private industry. Most recently, Ms. Freedholm was Vice President, Clinical Trial Solutions at Axiom Law.

Prior to joining the pharmaceutical industry, Ms. Freedholm spent 10 years as an ICU Nurse, Research Study Coordinator and Head Nurse of a Clinical Research Center. Ms. Freedholm has a Bachelor of Arts Degree in Nursing from Gustavus Adolphus College and an MBA from The Wharton School, University of Pennsylvania and has authored several peer-reviewed scientific papers and a text book chapter in the field of endocrinology and drug safety.